ABBV-706 + budigalimab

ABBV-706 + budigalimab is an investigational combination therapy for advanced solid tumors, particularly **small cell lung cancer (SCLC)**, high-grade central nervous system (CNS) tumors, and high-grade neuroendocrine carcinomas (NECs)[1][3][5][6]. - **ABBV-706** is an antibody-drug conjugate (ADC) targeting seizure-related homolog protein 6 (SEZ6), a transmembrane protein expressed in SCLC and other neuroendocrine neoplasms. ABBV-706 consists of an anti-SEZ6 monoclonal antibody conjugated to a topoisomerase 1 inhibitor payload, using a drug-to-antibody ratio of 6[1]. - **Budigalimab** is a monoclonal antibody targeting the programmed cell death 1 (PD-1) receptor, functioning as an immune checkpoint inhibitor. This combination aims to induce direct cytotoxicity via the ADC targeting SEZ6-positive tumor cells (ABBV-706), while budigalimab reactivates T-cell mediated anti-tumor immunity by antagonizing PD-1[3][5][6]. Both agents are administered intravenously.